Sensex, Nifty recover; Infosys supports, rupee hits 60/$.

The rupee touched 60 a dollar for the first time since May 12, 2014. Paul Mackel, MD & Head of Asian Currency Research at HSBC cautioned that the Indian rupee may weaken further if the current turmoil in Iraq worsens.

Granules India announced its Paracetamol facility successfully passed a US FDA inspection without any 483 observations. The facility has the world's largest single API production line by volume. Granules's four facilities have successfully passed US FDA inspections in the past 12 months. All of Granules' facilities including its finished dosage and PFI facility are approved by leading regulatory agencies including USFDA, EDQM, Health Canada and Korean FDA.

Power Grid to raise Rs 13,500 crore

Power Grid Corporation of India (PGCIL) is planning to raise around Rs 13,500 crore by way of private placement of bonds in the current fiscal. In this regard, the company is seeking approval of its shareholders. The proceeds would be used for capital expenditure. Earlier in March, the company’s board had approved raising up to Rs 16,500 crore this financial year (2014-15) to meet capital expenditure requirements. The amount of Rs 16,500 crore includes a proposed drawal of Rs 3,000 crore from Foreign Currency Committed Loans (FCCL) and Rs 2,000 crore from SBI term loan during the FY 2014-15, leaving untied debt of Rs 11,500 crore. PGCIL is India’s principal electric power transmission company. It owns and operates most of India’s interstate and inter-regional electric power transmission systems with inter-regional power transfer capacity of about 20,800 MW and wheels nearly 45% of total power generated across India.

Titagarh Wagons stock up 2%

The stock has hit a high of Rs295 and a low of Rs285.

Shares of Titagarh Wagons was up 2% at Rs 285 after the company reportedly said it has bagged a contract for rehabilitation of 56 coaches (7 rakes) from the Kolkata Metro Railway. The stock has hit a high of Rs295 and a low of Rs285.

Tata Motors’ Jaguar XF Sportbrake receives best-in-class award

Tata Motors’ British-based arm Jaguar and Land Rover’s (JLR) - Jaguar XF Sportbrake 3.0 V6 Diesel S has been named best-in-class for the third consecutive year at the Tow Car Awards 2014. A record 56 cars were tested for this year’s awards, with the XF Sportbrake crowned best in the hotly-contested class of cars weighing from 1700-1899 kg, with more than ten entries from the premium touring and SUV segments. Tata Motors is India's largest automobile company, is the leader in commercial vehicles in each segment, and among the top in passenger vehicles with winning products in the compact, midsize car and utility vehicle segments. It is also the world's fourth largest truck and bus manufacturer.

TCS launches brand new application ‘TCS SocialSoccer’

Tata Consultancy Services (TCS) has re-imagined the World Cup experience by launching a brand new application, TCS SocialSoccer, to give football fans a truly immersive social experience through their smartphones or tablets. This application will help soccer fans follow the online conversation during the tournament. By developing TCS SocialSoccer, TCS has created an app that allows football fans to track the mood and thoughts of fellow fans from around the world about teams, players and key events, aggregated in real-time. Using sophisticated algorithms, the application will aggregate real-time analysis of all matches based on Twitter data, tracking sentiment and key talking points from pundits, footballers and fans from across the globe. Besides, it allows users to follow all games and monitor the performance of their team and favourite players. The app is fully interactive, enabling fans to interact with other supporters, identify the biggest talking points from specific matches and monitor sentiment around their favourite teams or players.

Lupin gains on launching generic Cipro for oral suspension in US

Lupin is currently trading at Rs. 988.05, up by 4.10 points or 0.42% from its previous closing of Rs. 983.95 on the BSE. The scrip opened at Rs. 984.00 and has touched a high and low of Rs. 988.95 and Rs. 983.95 respectively. So far 3,016 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1022.00 on 07-May-2014 and a 52 week low of Rs. 742.30 on 28-Aug-2013. Last one week high and low of the scrip stood at Rs. 994.35 and Rs. 952.00 respectively. The current market cap of the company is Rs. 44,311.00 crore. The promoters holding in the company stood at 46.75% while Institutions and Non-Institutions held 43.17% and 10.08% respectively. Lupin’s US subsidiary, Lupin Pharmaceuticals Inc. (LPI) has launched its Ciprofloxacin for Oral Suspension, 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL) in the US having received final approval from the FDA earlier. Lupin’s Ciprofloxacin Oral Suspension, 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL) is the generic equivalent of Bayer HealthCare Pharmaceuticals, Inc.’s (Bayer) Cipro Oral Suspension 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL) and indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in various conditions and patient populations. Lupin is the first applicant to file an ANDA for Cipro Oral Suspension 250 mg/ml & 500 mg/ml and as such is entitled to 180 days of marketing exclusivity. Cipro Oral Suspension had annual US sales of $8.6 million, as per IMS MAT March, 2014.